“A strongly fluctuating and increased IOP is a particular risk factor for glaucoma patients. With eyemate it may succeed for the first time to have the IOP measured by the patient himself regularly and reliably. For us, the doctors, these self-measurements are very valuable. We are able to personalize therapies at an early stage and maintain vision in the event of a glaucoma risk.”
Prof. Hagen Thieme, Magdeburg
Director of the University Eye Hospital Magdeburg and head of the clinical trial ARGOS-02
